Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
0.8173
-0.0227 (-2.70%)
At close: Mar 19, 2026, 4:00 PM EDT
0.8190
+0.0017 (0.21%)
After-hours: Mar 19, 2026, 6:25 PM EDT
Heron Therapeutics Stock Forecast
HRTX's stock price has decreased by -67.04% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts that cover Heron Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $4.50, which forecasts a 450.59% increase in the stock price over the next year. The lowest target is $3.00 and the highest is $6.00.
Price Target: $4.50 (+450.59%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 9, 2026.
Analyst Ratings
The average analyst rating for Heron Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +634.12% | Jan 9, 2026 |
| Needham | Needham | Strong Buy Maintains $4 → $3 | Strong Buy | Maintains | $4 → $3 | +267.06% | Aug 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +634.12% | Jun 9, 2025 |
| Needham | Needham | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +389.42% | Apr 11, 2025 |
| Needham | Needham | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +389.42% | Feb 28, 2025 |
Financial Forecast
Revenue This Year
178.57M
from 154.90M
Increased by 15.28%
Revenue Next Year
214.81M
from 178.57M
Increased by 20.29%
EPS This Year
n/a
from -0.12
EPS Next Year
0.12
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 186.5M | 240.0M | |||
| Avg | 178.6M | 214.8M | |||
| Low | 169.5M | 188.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 20.4% | 34.4% | |||
| Avg | 15.3% | 20.3% | |||
| Low | 9.4% | 5.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.03 | 0.12 | |
| Avg | - | 0.12 | |
| Low | -0.03 | 0.11 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.